Want to see GOSS full AI Analyst Report?
GOSS Stock Chart & Stats
$0.20
>-$0.01(-4.56%)
At close: 4:00 PM EDT
$0.20
>-$0.01(-4.56%)
Day’s Range― - ―
52-Week Range$0.11 - $3.87
Previous CloseN/A
Volume10.93M
Average Volume (3M)36.28M
Market Cap
$85.69M
Enterprise Value$37.16
Total Cash (Recent Filing)$57.03M
Total Debt (Recent Filing)$39.10M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Nov 05, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding488,846,700
10 Day Avg. Volume18,363,918
30 Day Avg. Volume36,282,146
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-5.77
Price to Sales (P/S)14.62
P/FCF Ratio-4.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.07Price Target Upside435.00% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$38.39M
Bulls Say, Bears Say
Bulls Say
Seralutinib Clinical And Regulatory ProgressSeralutinib has generated clinically relevant efficacy and mechanistic imaging signals, while management has defined an NDA pathway and target date. These milestones create a credible route toward regulatory review and potential commercialization, although execution remains important.
Worldwide Control Of SeralutinibReacquiring worldwide rights gives Gossamer greater control over development, manufacturing, pricing, and future commercial economics. It also concentrates strategic decision-making around the lead asset, allowing the company to capture more value if regulatory and commercial milestones are achieved.
Financing Supports Development RunwayCommitted financing tied to regulatory milestones improves funding visibility for seralutinib’s late-stage development and potential commercialization. Extending expected operations into 2028 may reduce immediate funding pressure and provide more time to reach key regulatory and commercial milestones.
Bears Say
Persistent Losses And Heavy Cash BurnGossamer continues to consume substantial cash without recurring product revenue, while operating and net losses remain very large relative to its business scale. This weak cash-generation profile can require repeated external financing and limits flexibility to absorb delays or adverse development outcomes.
Negative Equity And Reduced Balance-sheet CushionNegative stockholders’ equity and a materially smaller asset base indicate limited balance-sheet resilience. The reduced financial cushion makes the company more dependent on successful financing and asset execution, while leaving less capacity to withstand prolonged losses, regulatory delays, or development setbacks.
Clinical And Regulatory UncertaintyAlthough the primary endpoint met the traditional 0.05 threshold, it missed the study’s stricter prespecified alpha. That shortfall creates uncertainty over how regulators will interpret the evidence and could complicate NDA review, approval timing, labeling, or the need for additional support.
Gossamer Bio News
GOSS FAQ
What was Gossamer Bio Inc’s price range in the past 12 months?
Gossamer Bio Inc lowest stock price was $0.11 and its highest was $3.87 in the past 12 months.
What is Gossamer Bio Inc’s market cap?
Gossamer Bio Inc’s market cap is $85.69M.
When is Gossamer Bio Inc’s upcoming earnings report date?
Gossamer Bio Inc’s upcoming earnings report date is Nov 05, 2026 which is in 58 days.
How were Gossamer Bio Inc’s earnings last quarter?
Gossamer Bio Inc released its earnings results on Aug 13, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.123 by $0.043.
Is Gossamer Bio Inc overvalued?
According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued.
Does Gossamer Bio Inc pay dividends?
Gossamer Bio Inc does not currently pay dividends.
What is Gossamer Bio Inc’s EPS estimate?
Gossamer Bio Inc’s EPS estimate is -0.05.
How many shares outstanding does Gossamer Bio Inc have?
Gossamer Bio Inc has 488,846,700 shares outstanding.
What happened to Gossamer Bio Inc’s price movement after its last earnings report?
Gossamer Bio Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.123. Following the earnings report the stock price went down -9.412%.
Which hedge fund is a major shareholder of Gossamer Bio Inc?
Currently, no hedge funds are holding shares in GOSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gossamer Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.07 (435.00% Upside)
$1.07 (435.00% Upside)
Blogger Sentiment
Bullish
GOSS Sentiment 67%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-68.09%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
GOSS Company Deck
GOSS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: clinically meaningful efficacy signals (including a traditional statistical threshold for 6MWD), supportive mechanistic CT FRI data across multiple lung compartments with clinical correlations, and decisive capital actions (debt reduction plan and cost containment) to preserve runway and focus on an NDA path. Counterbalancing these positives were key execution risks — the primary endpoint did not meet the prespecified alpha, a substantial workforce reduction was implemented, cash runway is short ($99M to Q1 2027), and the debt exchange depends on high noteholder participation and involves tradeoffs. Overall, the tone is cautious and pragmatic, emphasizing strengthened conviction in the program but acknowledging material near-term financial and regulatory risks.View all GOSS earnings summariesGOSS Stock 12 Month Forecast
Average Price Target
$1.07
▲(435.00% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Cue Biopharma
―
Tiziana Life Sciences
―
Alector
―
Connect Biopharma Holdings
―
Ownership Overview
1.86% Insiders
3.62% Mutual Funds
38.41% Other Institutional Investors
52.09% Public Companies and
Individual Investors